Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta
Fröba et al., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro)
Fröba et al., Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma.., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro)
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study of iota-, lambda-, and kappa-carrageenan sulfated polysaccharides extracted from red seaweed on SARS-CoV-2 Wuhan type and variants Alpha, Beta, Gamma and Delta, showing that all three carrageenan types had antiviral activity. Iota-carrageenan had comparable IC50 values against all variants. Authors conclude that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 for existing and potentially future variants.
9 In Vitro studies support the efficacy of iota-carrageenan [Alsaidi, Bansal, Bovard, Fröba, Meister, Morokutti-Kurz, Morokutti-Kurz (B), Song, Varese].
Fröba et al., 8 Dec 2021, peer-reviewed, 14 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperIota-carragee..All
Abstract: International Journal of Molecular Sciences Article Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta Maria Fröba 1,† , Maximilian Große 1,† , Christian Setz 1,† , Pia Rauch 1 , Janina Auth 1 , Lucas Spanaus 1 , Jan Münch 2 , Natalia Ruetalo 3 , Michael Schindler 3 , Martina Morokutti-Kurz 4 , Philipp Graf 4 , Eva Prieschl-Grassauer 4 , Andreas Grassauer 4 and Ulrich Schubert 1, * 1 2 3 4   Citation: Fröba, M.; Große, M.; Setz, C.; Rauch, P.; Auth, J.; Spanaus, L.; Münch, J.; Ruetalo, N.; Schindler, M.; Morokutti-Kurz, M.; et al. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. Int. J. Mol. Sci. 2021, 22, 13202. https://doi.org/ 10.3390/ijms222413202 Academic Editor: Giovanni Maga Received: 21 October 2021 Accepted: 3 December 2021 Published: 8 December 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. * † Institute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Maria.Carolin.Froeba@fau.de (M.F.); Maximilian.Grosse@uk-erlangen.de (M.G.); Christian.Setz@uk-erlangen.de (C.S.); Pia.Rauch@uk-erlangen.de (P.R.); Janina.Auth@fau.de (J.A.); Lucas.Spanaus@extern.uk-erlangen.de (L.S.) Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany; Jan.Muench@uni-ulm.de Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, 72076 Tübingen, Germany; Natalia.Ruetalo-Buschinger@med.uni-tuebingen.de (N.R.); Michael.Schindler@med.uni-tuebingen.de (M.S.) Marinomed Biotech AG, A-2100 Korneuburg, Austria; Martina.Morokutti-Kurz@marinomed.com (M.M.-K.); Philipp.Graf@marinomed.com (P.G.); Eva.Prieschl@marinomed.com (E.P.-G.); Andreas.Grassauer@marinomed.com (A.G.) Correspondence: Ulrich.Schubert@fau.de; Tel.: +49-9131-85-26478 These authors are contributed equally to this work. Abstract: The COVID-19 pandemic continues to spread around the world and remains a major public health threat. Vaccine inefficiency, vaccination breakthroughs and lack of supply, especially in developing countries, as well as the fact that a non-negligible part of the population either refuse vaccination or cannot be vaccinated due to age, pre-existing illness or non-response to existing vaccines intensify this issue. This might also contribute to the emergence of new variants, being more efficiently transmitted, more virulent and more capable of escaping naturally acquired and vaccine-induced immunity. Hence, the need of effective and viable prevention options to reduce viral transmission is of outmost importance. In this study, we investigated the antiviral effect of iota-, lambda- and kappa-carrageenan, sulfated polysaccharides extracted from red seaweed, on SARS-CoV-2 Wuhan type and the spreading variants of concern (VOCs) Alpha, Beta, Gamma and Delta. Carrageenans as part of broadly used nasal and mouth sprays as well as lozenges have the potential of first line defense to inhibit the infection and transmission of SARS-CoV-2. Here, we demonstrate by using a SARS-CoV-2 spike pseudotyped lentivirus particles (SSPL) system and patient-isolated SARS-CoV-2 VOCs to infect transgenic A549ACE2/TMPRSS2 and Calu-3 human lung cells that all three carrageenan types exert antiviral activity. Iota-carrageenan exhibits antiviral activity with..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit